Table 2.

Key characteristics of patients treated with immune checkpoint blockade.

Characteristic	Total N = 15 (%)
Treatment
Anti-PD1 * Anti-PD-L1 ** Anti-PD-1 + anti-CTLA4 *** Platinum-based chemotherapy + anti-PD1 †	10 (66.7) 2 (13.3) 1 (6.7) 2 (13.3)
Line of immune checkpoint blockade administration
1st ≥2nd	6 (40.0) 9 (60.0)
PS prior to immune checkpoint blockade
0–1 2	11 (73.3) 4 (26.7)

PD-1, programmed death-1; PD-L1, programmed death ligand-1; PS, performance status; * 6 patients pembrolizumab and 4 patients nivolumab; ** 2 patients atezolizumab; *** Nivolumab + ipilimumab; ^† 2 patients platinum-pemetrexed + pembrolizumab.